AU2021244209A1 - Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer - Google Patents

Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer Download PDF

Info

Publication number
AU2021244209A1
AU2021244209A1 AU2021244209A AU2021244209A AU2021244209A1 AU 2021244209 A1 AU2021244209 A1 AU 2021244209A1 AU 2021244209 A AU2021244209 A AU 2021244209A AU 2021244209 A AU2021244209 A AU 2021244209A AU 2021244209 A1 AU2021244209 A1 AU 2021244209A1
Authority
AU
Australia
Prior art keywords
group
chd1l
alkyl
optionally substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021244209A
Other languages
English (en)
Inventor
Joshua M. ABBOTT
Hector ESQUER
Daniel V. Labarbera
Brett Joseph PRIGARO
Qiong ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Publication of AU2021244209A1 publication Critical patent/AU2021244209A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021244209A 2020-03-24 2021-03-24 Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer Pending AU2021244209A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994259P 2020-03-24 2020-03-24
US62/994,259 2020-03-24
US202163139394P 2021-01-20 2021-01-20
US63/139,394 2021-01-20
PCT/US2021/023981 WO2021195279A2 (en) 2020-03-24 2021-03-24 Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer

Publications (1)

Publication Number Publication Date
AU2021244209A1 true AU2021244209A1 (en) 2022-11-03

Family

ID=77892666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021244209A Pending AU2021244209A1 (en) 2020-03-24 2021-03-24 Small molecule inhibitors of oncogenic CHD1L with preclinical activity against colorectal cancer

Country Status (6)

Country Link
EP (1) EP4127209A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023520330A (cg-RX-API-DMAC7.html)
CN (1) CN115667553A (cg-RX-API-DMAC7.html)
AU (1) AU2021244209A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172987A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021195279A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525158A (ja) * 2021-06-17 2024-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア E3リガーゼ阻害剤及びその使用方法
AU2022354855A1 (en) * 2021-09-30 2024-04-18 The Regents Of The University Of Colorado, A Body Corporate Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer
CN114457007B (zh) * 2022-02-28 2024-05-28 合肥燃音生物科技有限公司 一种基于微孔板的均一的单类器官模型及其制备方法
CN119365198A (zh) * 2022-05-02 2025-01-24 艾斯巴赫生物有限公司 ALC1抑制剂的用途和与PARPi的协同作用
CN115290774B (zh) * 2022-07-21 2023-07-21 重庆医科大学 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用
WO2024211314A2 (en) * 2023-04-03 2024-10-10 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of chd1l and uses thereof
CN122070131A (zh) 2023-10-25 2026-05-19 艾斯巴赫生物有限公司 在同源重组缺陷型(hrd)癌症的治疗中使用的作为alc1抑制剂的吡啶并噻吩并嘧啶衍生物
AU2024366320A1 (en) * 2023-10-25 2026-04-16 Eisbach Bio Gmbh Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
WO2025093706A1 (en) * 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan
WO2025129032A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Chd1l inhibitors for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211603A1 (en) * 2004-08-18 2006-09-21 Vicuron Pharmaceuticals Inc. Ramoplanin derivatives possessing antibacterial activity
SG10201500124VA (en) * 2010-01-08 2015-03-30 Agency Science Tech & Res Methods and Compositions for Treating Cancer
WO2012166722A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
MX355354B (es) * 2012-08-23 2018-04-17 Virostatics Srl Derivados aminopirimidinicos 4,6-disustituidos novedosos.
US20160138114A1 (en) * 2013-06-19 2016-05-19 The Regents Of The University Of California Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
CN109761909B (zh) * 2019-01-25 2022-08-26 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途

Also Published As

Publication number Publication date
CA3172987A1 (en) 2021-09-30
EP4127209A2 (en) 2023-02-08
WO2021195279A3 (en) 2021-11-11
JP2023520330A (ja) 2023-05-17
CN115667553A (zh) 2023-01-31
WO2021195279A2 (en) 2021-09-30
EP4127209A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
WO2021195279A2 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
US11452725B2 (en) Chiral diaryl macrocycles and uses thereof
ES2977196T3 (es) Inhibidores de receptor de ERBB
JP6869947B2 (ja) 置換キナゾリン化合物ならびにそのg12c変異kras、hrasおよび/またはnrasタンパク質の阻害剤としての使用
JP6789239B2 (ja) Krasの縮合三環系インヒビターおよびその使用の方法
US20250101043A1 (en) Kras inhibitors
JP2021020957A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
CN106488910A (zh) Kras g12c的抑制剂
KR20230065261A (ko) 자가면역질환 및 암 치료용 저분자 화합물
WO2022032224A1 (en) Compositions and methods for the treatment and diagnosis of cancer
JP2018513214A (ja) 新規なキナーゼ阻害剤の調製と使用
US20230103444A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
WO2024211314A2 (en) Inhibitors of chd1l and uses thereof
US20190031639A1 (en) Zuclopenthixol hydrochloride derivatives and ebselen derivatives as erbb2 inhibitors
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
CN112010789A (zh) 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
AU2022354855A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectral cancer
US20240016795A1 (en) Bromodomain inhibitors for androgen receptor-driven cancers
HK40087586A (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
US10550114B2 (en) Kinase inhibitors and their use in cancer therapy
US20250122193A1 (en) Novel pyridocarbazolium compounds and medical uses thereof
RU2810215C2 (ru) Ингибиторы рецепторов erbb
WO2024249554A1 (en) Multitarget small molecule inhibitors and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LABARBERA, DANIEL V.; ABBOTT, JOSHUA M.; ZHOU, QIONG; ESQUER, HECTOR AND PRIGARO, BRETT JOSEPH